Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Radioimmunotherapy with engineered antibodies.

Maria G Russeva1, Gregory P Adams

  • 1Department of Medical Oncology, Fox Chase Cancer Center, 7701 Burholme Avenue, Philadelphia, PA 19111, USA.

Expert Opinion on Biological Therapy
|March 5, 2004
PubMed
Summary

Recent antibody engineering advances are making radioimmunotherapy (RAIT) successful for cancer treatment. New strategies overcome past limitations, paving the way for effective targeted radiation therapy.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Ultrasmall Folate Receptor Alpha Targeted Enzymatically Cleavable Silica Nanoparticle Drug Conjugates Augment Penetration and Therapeutic Efficacy in Models of Cancer.

ACS nano·2022
Same author

CAR T Cells Targeting MISIIR for the Treatment of Ovarian Cancer and Other Gynecologic Malignancies.

Molecular therapy : the journal of the American Society of Gene Therapy·2019
Same author

Molecular Simulation of Receptor Occupancy and Tumor Penetration of an Antibody and Smaller Scaffolds: Application to Molecular Imaging.

Molecular imaging and biology·2017
Same author

DeBouganin Diabody Fusion Protein Overcomes Drug Resistance to ADCs Comprised of Anti-Microtubule Agents.

Molecules (Basel, Switzerland)·2016
Same author

Antibody Engineering & Therapeutics 2016: The Antibody Society's annual meeting, December 11-15, 2016, San Diego, CA.

mAbs·2016
Same author

Trastuzumab-deBouganin Conjugate Overcomes Multiple Mechanisms of T-DM1 Drug Resistance.

Journal of immunotherapy (Hagerstown, Md. : 1997)·2016

Area of Science:

  • Oncology
  • Immunology
  • Biotechnology

Background:

  • Monoclonal antibody technology enabled targeted radioisotopes for tumors since the 1970s.
  • Early radioimmunotherapy (RAIT) clinical trials faced significant challenges and were largely unsuccessful.
  • Previous RAIT failures were attributed to specific factors limiting efficacy and safety.

Purpose of the Study:

  • To review recent advancements in antibody engineering for RAIT.
  • To discuss updated RAIT strategies addressing historical limitations.
  • To highlight the potential of modern RAIT in cancer treatment.

Main Methods:

  • Review of molecular biology techniques for antibody re-engineering.
  • Analysis of novel antibody formats and conjugation strategies.
  • Examination of improved targeting and pharmacokinetic approaches in RAIT.

Main Results:

  • Significant progress in engineering antibodies with enhanced tumor targeting and retention.
  • Development of more effective radioisotope payloads and delivery systems.
  • Demonstration of improved therapeutic indices in preclinical and early clinical studies.

Conclusions:

  • Antibody engineering has overcome key obstacles in RAIT.
  • Current RAIT strategies show promise for successful cancer therapy.
  • The field is poised for clinical translation and broader application.

Related Experiment Videos